Association between lipid peroxidation and inflammation in obstructive sleep apnoea

European Respiratory Journal

Volumn 28, Issue 2, 2006, Pages 378-385

  Minoguchi, K ^a   Yokoe, T ^a   Tanaka, A ^a   Ohta, S ^a   Hirano, T ^a   Yoshino, G ^b   O'Donnell, C P ^c   Adachi, M ^a  

^a SHOWA UNIVERSITY   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Cardiovascular diseases; Hypoxia; Inflammation; Oxidative stress; Sleep apnoea

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; INDEPENDENT VARIABLE; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SLEEP; SLEEP APNEA SYNDROME; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DINOPROST; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MALE; MIDDLE AGED; OBESITY; SLEEP APNEA, OBSTRUCTIVE;

EID: 33845475440     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00084905     Document Type: Article

References (45)

1. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
2. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea. A 7-year follow up. Am J Respir Crit Care Med 2002; 166: 159-165.
3. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
4. Marti S, Sampol G, Munoz X, et al. Mortality in severe sleep apnoea/ hypopnoea syndrome patients: impact of treatment. Eur Respir J 2002; 20: 1511-1518.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
6. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-516.
7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
8. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 1139-1147.
9. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019-2023.
10. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
11. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126: 1473-1479.
12. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med 1996; 153: 1080-1086.
13. Chin K, Nakamura T, Shimizu K, et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000; 109: 562-567.
14. Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002; 165: 67-70.
15. Tazaki T, Minoguchi K, Yokoe T, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 170: 1354-1359.
16. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625-630.
17. Dean RT, Wilcox I. Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 1993; 16: Suppl. 8, S15-S22.
18. Lavie L. Obstructive sleep apnoea syndrome - oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
19. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000; 162: 566-570.
20. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-939.
21. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
22. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655-673.
23. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 24441-24444.
24. Carpagnano GE, Kharitonov SA, Resta O, et al. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002; 122: 1162-1167.
25. Carpagnano GE, Kharitonov SA, Resta O, et al. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-1392.
26. The Report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommedations for syndrome definition and measurement techniques in clinical research. Sleep 1999; 22: 667-589.
27. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-554.
28. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971-976.
29. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220.
30. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177.
31. Collins CE, Quaggiotto P, Wood L, O'Loughlin EV, Henry RL, Garg ML. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids 1999; 34: 551-556.
32. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158: 1524-1527.
33. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-128.
34. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16: 644-647.
35. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-isoprostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-848.
36. Prabhakar NR. Sleep apneas: an oxidative stress? Am J Respir Crit Care Med 2002; 165: 859-860.
37. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
38. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
39. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. Hypertension 2002; 39: 777-780.
40. Abramson JL, Hooper WC, Jones DP, et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005; 178: 115-121.
41. Lee DH, Jacobs Jr DR. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178: 327-330.
42. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
43. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003; 23: 1398-1404.
44. Waddington EI, Puddey IB, Mori TA, Croft KD. Similarity in the distribution of F(2)-isoprostanes in the lipid subtractions of atherosclerotic plaque and in vitro oxidised low density lipoprotein. Redox Rep 2002; 7: 179-184.
45. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and isulin resistance in men. J Clin Endocrinol Metab 2003; 88: 4673-4676.